MedPage Today on MSN
Preop RT May Boost Response to Chemo-Immunotherapy in High-Risk Early Breast Cancer
SAN ANTONIO -- Preoperative radiotherapy (RT) plus PD-1 inhibitor pembrolizumab (Keytruda) significantly increased immune ...
Preoperative radiation improved T-cell infiltration among patients with hormone receptor-positive, HER2-negative breast ...
3don MSN
Preoperative radiation may improve antitumor immune response in most common form of breast cancer
Preoperative radiation improved T-cell infiltration (TCI) in patients with hormone receptor (HR)-positive, HER2-negative ...
TipRanks on MSN
Lytix Biopharma’s promising update: Phase 2 study on advanced melanoma treatment completed
Lytix Biopharma AS ($DE:6BG) announced an update on their ongoing clinical study. Study Overview: The clinical study titled A Phase 2 Study of ...
The totality of the data suggests that a higher dose of ficerafusp alfa with greater TGF-β inhibition and immune activation drives deeper tumor responses that translate to more durable outcomes for ...
FDA approves pembrolizumab and enfortumab vedotin for neoadjuvant and adjuvant treatment of cisplatin-ineligible muscle-invasive bladder cancer.
In this study, researchers investigated long-term outcomes from a real-world cohort of patients with stage IV melanoma treated with pembrolizumab following progression on prior therapies.
Early MRI predicts pathologic complete response and long-term outcomes in TNBC patients receiving pembrolizumab.
Sacituzumab govitecan and pembrolizumab showed a manageable safety profile in PD-L1–positive metastatic TNBC, with lower dose reduction or discontinuation rates than chemotherapy. The combination ...
Licensing partner Zydus brings extensive commercial experience, marketing more than 225 FDA-approved medicines, providing a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback